SeaStar Medical Holding Corporation (ICU) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
SeaStar Medical Holding Corporation stock (ICU) is currently trading at $2.28. SeaStar Medical Holding Corporation PS ratio (Price-to-Sales) is 9.62. Analyst consensus price target for ICU is $9.00. WallStSmart rates ICU as Sell.
- ICU PE ratio analysis and historical PE chart
- ICU PS ratio (Price-to-Sales) history and trend
- ICU intrinsic value — DCF, Graham Number, EPV models
- ICU stock price prediction 2025 2026 2027 2028 2029 2030
- ICU fair value vs current price
- ICU insider transactions and insider buying
- Is ICU undervalued or overvalued?
- SeaStar Medical Holding Corporation financial analysis — revenue, earnings, cash flow
- ICU Piotroski F-Score and Altman Z-Score
- ICU analyst price target and Smart Rating
SeaStar Medical Holding Corporation
📊 No data available
Try selecting a different time range
Smart Analysis
SeaStar Medical Holding Corporation (ICU) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
SeaStar Medical Holding Corporation (ICU) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 169.10% year-over-year
Supporting Valuation Data
SeaStar Medical Holding Corporation (ICU) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 9.6x annual revenue
Very low institutional interest at 6.28%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
SeaStar Medical Holding Corporation (ICU) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.75) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 169.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (9.62) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -290.40%, Operating Margin at -1956.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -290.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 169.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ICU Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ICU's Price-to-Sales ratio of 9.62x sits near its historical average of 10.94x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 19% below its historical high of 11.95x set in Mar 2026, and 0% above its historical low of 9.62x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~11.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for SeaStar Medical Holding Corporation (ICU) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
SeaStar Medical Holding Corporation is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 881,000 with 169% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 169% YoY, reaching 881,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 210% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can SeaStar Medical Holding Corporation maintain 169%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact SeaStar Medical Holding Corporation.
Bottom Line
SeaStar Medical Holding Corporation is a high-conviction growth story with revenue accelerating at 169% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About SeaStar Medical Holding Corporation(ICU)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
SeaStar Medical Holding Corporation (ICU) is an innovative biotechnology company at the forefront of developing advanced therapies for chronic kidney disease. By harnessing proprietary technologies aimed at improving renal function and minimizing the need for invasive interventions, SeaStar addresses significant unmet medical needs within a large and growing market. With a strong emphasis on research and development, the company is well-positioned to drive progress in renal health, supported by strategic partnerships and a commitment to clinical excellence that are anticipated to accelerate the commercialization of its groundbreaking therapeutic solutions.